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Abstract: This study considers the influence of exposure to simulated gastrointestinal condi-
tions (saliva, gut, intestine and acidic conditions of the gut) on IgG binding of unmodified al-
lergens and three types of LMW allergoids of Artemisia vulgaris pollen extract obtained by
means of potassium cyanate, succinic and maleic anhydride. It also concerns the optimiza-
tion of a self-developed ELISA assay for comparison of the specific IgG binding of
mugwort pollen extract and modified mugwort pollen derivatives. The ELISA was con-
ducted with a mugwort pollen extract coupled to the plate, using the sera from 12 mug-
wort-pollen allergic patients. The exposure to saliva fluid for 2 min did not influence the IgG
binding properties of allergens and allergoids. Exposure of mugwort pollen allergens and
LMW allergoids to the acidic conditions of the gut did not dramatically change their IgG
binding properties. By exposing mugwort pollen extract and LMW derivatives to the SGF
conditions for 1 h, the percent of IgG binding epitopes was reduced to a half of its starting
value in the extract and to about 30 % in all the allergoid samples. After prolonged exposure
only the carbamyl derivative showed reduced IgG binding. Changes of the IgG binding po-
tential of all four samples after exposure in SIF followed a similar pattern.
Keywords: simulated gastrointestinal conditions, Artemisia vulgaris, mugwort, pollen, aller-
goid.
INTRODUCTION
Different forms of local immunotherapies of allergic diseases1–4 as well as chemical
modification of allergens were mainly considered to be a safe way of administering aller-
genic extracts. In local forms of immunotherapy, some low-molecular weight allergoids
could also find application. Low-molecular weight (LMW) derivatives of allergens are
modified forms of allergens of the same (native) size as the unmodified ones. Two
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prinicpal approaches were undertaken to obtain LMW allergoids: carbamylation5–7 and
acid anhydrides treatment.8,9 Such derivatives reduce the allergenicity while preserving
the ability to induce blocking of IgG antibodies, whose increased level during aller-
gen-specific immunotherapy correlates well with clinical improvements.10 Thus, the re-
tention of IgG-binding epitopes on the modified allergens is of significance in the protec-
tion against harmful effects of IgE-mediated allergic reactions that could appear during lo-
cal allergen delivery throughout the gastrointestinal tract of an allergic person, especially
because it has been shown that there is a fraction of IgG antibodies in mucosal secretions
that contributes to the immunity of mucosa, besides IgA antibodies.10
A study of the digestion stability of birch, timothy, ragweed and mugwort pollen ex-
tracts showed a remarkable difference among the investigated allergenic extracts. Mugwort
pollen extract was shown to be the source of the most resistant allergens. Adouble-band frac-
tion of 28 – 35 kD was isolated from mugwort pollen which was a pepsin-resistant aller-
gen.11 Moreover, its prolonged and limited digestion in the gut could raise the question of
higher incidence rates of side-effects during local immunotherapy trials. Regarding this, a
better knowledge of how the mugwort pollen derivatives behave in simulated conditions of
the gut, might be important in optimizing the dosage of the extracts used in local forms of
immunotherapy conducted with allergenic extracts rich in these pepsin-resistant allergens.
This study considers the dependence of exposure to simulated in vivo gastrointestinal
conditions on the IgG binding of three types of LMW allergoids of Artemisia vulgaris pol-
len extract. Although all three reactants act on the -amino group of Lys, the bonds formed
in such a way differ in chemical stability as well as stereochemistry
12 and yield quite dif-
ferent modification products. A self-developed ELISA assay was also optimized to com-
pare the specific IgG binding of untreated mugwort pollen extract and modified mugwort
pollen derivatives.
RESULTS AND DISCUSSION
Human sera: The characteristics of the group of patients included in the study (8 men
and 4 women; aged 28 – 55) are shown in Table I. For the pool used in the ELISAtesting,
the values for the total and specific IgE were determined to be: 586 kUA/l and 12.8 kUA/l,
respectively.
IgG binding: The values obtained for the IgG binding of untreated samples were in
the order: mugwort pollen sample, carbamyl derivative, maleyl derivative and succinyl de-
rivative. The values were in agreement with published observations that the succinyl deriv-
ative binds IgG from the pool of the sera of allergic patients to a lesser extent than the other
samples tested. According to the majority of the assays included in a previous study, the
succinyl modification gave derivatives with the most changed IgE and IgG binding prop-
erties when compared to the native sample.
The influence of saliva exposure. The exposure to saliva fluid for 2 min did not influ-
ence the IgG binding properties of allergens and allergoids, as demonstrated by measuring
the residual IgG binding in the samples (Figs. 1–4). In sublingual forms of IT, 2 min ab-
sorption through mucosa did not change the properties of the derivatives introduced. With
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respect to the side-effects of SLIT on the mouth (itching and oedema),1,13 the stability of
the derivatives tested is very important.
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Fig. 2. ELISA inhibition of IgG binding for maleyl derivatives of mugwort pollen proteins before and after
simulated gastrointestinal exposure. Control-non treated maleyl derivatives of mugwort pollen proteins; sa-
liva-saliva treated sample; 1 h-sample after 1 h treatment with the acidic conditions of the gut; 4 h-sample
after 4 h treatment with the acidic conditions of the gut; sgf*-simulated gastric juice treated sample;
sif*-simulated intestine juice treated sample; 1 h, 2 h and 4 h-duration of the treatment.
Fig. 1. ELISA inhibition of IgG binding for mugwort pollen extract before and after simulated gastrointesti-
nal exposure. Control-non treated mugwort pollen proteins; saliva-saliva treated sample; 1 h-sample after 1
h treatment with the acidic conditions of the gut; 4 h-sample after 4 h treatment with the acidic conditions of
the gut; sgf*-simulated gastric juice treated sample; sif*-simulated intestine juice treated sample; 1 h, 2 h
and 4 h-duration of the treatment.
The influence of exposure to the acidic conditions of gastric fluid. According to the
percent of residual IgG binding, after 4 h of gastric exposure, the acyl derivatives start to
hydrolyze (Figs. 2 and 3), liberating IgG epitopes blocked by the modification reaction.
The carbamyl derivative did not change its IgG binding potential in the very acidic condi-
tions of the gut environment (Fig. 4).
The influence of exposure to gastric fluid. On exposing the mugwort pollen extract
(Fig. 1) and the low-molecular derivatives to simulated gastric fluid (SGF) conditions for 1
h (Figs. 2–4), the percent of IgG binding epitopes was reduced to half of its starting value.
In all the samples, the residual protein remained fully resistant to digestion and contributed
to IgG binding. Its IgG binding potential was still below the value of the native extract,
however, a significant proportion of almost 75 % of the IgG binding epitopes remained in
the modified derivatives when compared to the native sample.
TABLE I. Patient's clinical characteristics
Patient's No. Sex Current age/y Diagnosis
Prick testing with mugwort pollen
(weal/flare mm)
1 F 27 Allergic rhinoconjunctivitis 6/20
2 F 53 Pollinosis 7/15
3 M 53 Pollinosis 4/7
4 F 30 Allergic rhinitis 10/20
5 M 32 Pollinosis 8/11
6 F 49 Allergic rhinitis 7/10
7 M 49 Allergic rhinitis, Laryngitis 8/18
8 M 55 Allergic rhinitis 5/8
9 M 48 Pollinosis 6/9
10 M 32 Allergic rhinitis 5/10
11 M 30 Pollinosis 4/10
12 M 57 Allergic rhinitis 8/13
The influence of exposure to intestine fluid. Although exposure to SIF conditions sig-
nificantly reduces the allergenic potential of the derivatives,11 presumably by digestion of
the pepsin resistant mugwort pollen allergen, the IgG binding potential after 2 h exposure
was similar to the SGF treated samples after 1 h (Figs. 1–4). Aportion of the residual pep-
tide fragments contributed to the extent of inhibition.
Pollen allergens are generally believed to be labile under the conditions of the gut en-
vironment. Some earlier reports suggest rapid degradation of grass and tree pollen proteins
in the gut and duodenal fluids.14–17
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Regarding the observation that not all of the pollen allergens degrade rapidly10 and
possible immunotherapy trials of acid anhydride derivatives, it was important to investi-
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Fig.4. ELISA inhibiton of IgG binding for carbamyl derivatives of mugwort pollen proteins before and after
simulated gastrointestinal exposure. Control-non treated carbamyl derivatives of mugwort pollen proteins;
saliva-saliva treated sample; 1 h-sample after 1 h treatment with the acidic conditions of the gut; 4 h-sample
after 4 h treatment with the acidic conditions of the gut; sgf*-simulated gastric juice treated sample;
sif*-simulated intestinge juice treated sample; 1 h, 2 h and 4 h-duration of the treatment.
Fig. 3. ELISA inhibition of IgG binding for succinyl derivatives of mugwort pollen proteins before and after
simulated gastrointestinal exposure. Control-non treated succinyl derivatives of mugwort pollen proteins;
saliva-saliva treated sample; 1 h-sample ofter 1 h treatment with the acidic conditions of the gut; 4 h-sample
after 4 h treatment with the acidic conditions of the gut; sgf*-simulated gastric juice treated sample;
sif*-simulated intestine juice treated sample; 1 h, 2 h and 4 h-duration of the treatment.
gate the IgG binding properties of these derivatives in the simulated environments of pa-
tients' saliva, gut and intestine, in order to achieve a fine tuning of the local immunotherapy
dosage of these derivatives.
This study showed that the retention of IgG binding epitopes in the modified deriva-
tives is greater than that of the unmodified sample. One of the reasons might be a reduced
hydrolysis of the derivatives in the acidic conditions of the gut (as seen after 4 h exposure),
but also the modifications might protect the derivatives against proteolitic cleavage. Addi-
tionally, the effect of deacylation on the extent of IgG binding is of greater magnitude when
compared to the IgE binding of the same samples.11 As most of the proteins both in the na-
tive and modified samples are degraded under SIF conditions, the blocking effect is more
pronounced regarding the simulated intestinal conditions, presumably because of the pro-
tecting effect on the -amino group of Lys, the target of trypsin, which is the main compo-
nent of pancreatin juice.
EXPERIMENTAL
Allergen and allergoids preparations. Pollen extracts as well as the modified derivatives were prepared
as described previously.8,9,18 The carbamyl derivative was prepared according to Mistrello et al.5 The protein
concentrations were determined by the Bradford method.19
The simulated saliva experiments. The simulated saliva fluid (SSF) consisted of 2.38 g Na2HPO4, 0.19
g KH2PO4, 8 g NaCl/l adjusted with phosphoric acid to pH 6.75. 150 g of allergoids and unmodified sam-
ples were exposed to 150 l SSF for 2 min at 37 ºC. After exposure the samples were immediately transferred
to an ice-bath and kept frozen until analyzed.
The simulated gastric juice experiments. The simulated gastric fluid (SGF) consisted of 0.1 M HCl, 2 g/L
NaCl and 3.2 g/L pepsin (Sigma). The same fluid was prepared without addition of pepsin. The allergens and
alelrgoids were exposed to SGF both with and without pepsin for 1 and 4 hours in accordance with conditions de-
scribed earlier.20 The reaction was stopped by the addition of 1 M sodium bicarbonate to the pH value of 7.2.
The simulated intestine juice experiments. The simulated intestine fluid consisted of phosphate buffer
pH 7.4, and 10 g/l of pancreatin (Sigma) in accordance with US Pharmacopoeia. The samples were exposed
to SIF for 2 and 4 hours. The reaction was stopped by freezing the sample.
Human sera. The sera from 12 patients with a documented clinical history of mugwort pollen allergy
and with a recorded course of specific immunotherapy to mugwort pollen were used. The patients had docu-
mented clinical histories of allergic rhinitis, allergic asthma, allergic rhinoconjunctivitis and allergic conjunc-
tivitis. Sera from five non-atopic persons were pooled and used as a control. The values of the total and
mugwort pollen specific IgE in the pooled sera were determined by the UniCap (Pharmacia, Uppsala, Swe-
den) system.
ELISA and ELISA inhibition. ELISAs were performed as described previously.21 Briefly, microtiter
plates (Nunc, Maxi sorp) were coated with 50 l of mugwort extract (7 g/ml) overnight at room temperature
and washed with TBS/0.1 % Tween 20. After blocking with 100 l of 1 % BSA in TBS/0.1 % Tween 20, 50
l of six-fold diluted pooled human sera, incubated with 50 l of diluted allergen or allergoids (at the concen-
tration of 4 g/ml) in tubes for 30 min at 4 ºC, were added to the plates. The saliva, SGF and SIF exposed
samples were diluted to the same volume as were untreated proteins. As a positive control, the human serum
pool was incubated with saliva, SGF or SIF solutions diluted to the same volume as the samples and
ovalbumin of the same concentrations as the samples or with TBS alone. For inhibition, diluted solutions of
all samples were prepared with a diluting buffer consisting of TBS-0.5 % BSA. Human sera from persons
with negative skin tests to mugwort pollen extract was used as a negative control. As a second antibody,
anti-human IgG antibody labelled alkaline phosphatase (Sigma) was used. The absorbance values were mea-
sured at 405 nm after adjusting the background with a negative control. The percent of inhibiton was calcu-
lated in accordance with the formula previously described
21 and from the appropriate positive control.
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I Z V O D
IgG VEZIVAWE ALERGENA I ALERGOIDA POLENA PELINA PRETHODNO
IZLO@ENIH SIMULIRANIM USLOVIMA GASTROINTESTINALNOG
TRAKTA MERENO DOMA]IM ELISA TESTOM
NATALIJA \. POLOVI]*, TAWA D. ]IRKOVI]–VELI^KOVI]*, MARIJA \.
GAVROVI]-JANKULOVI]*, LIDIJA BURAZER**, DANICA \ERGOVI]-PETROVI]**, OLGA
VU^KOVI]** i RATKO M. JANKOV*
*Hemijski fakultet, Studentski trg 16, 11000 Beograd i **Institut za imunologiju i virusologiju, Torlak,
Vojvode Stepe 458, 11221 Beograd
Predmet ovog rada je ispitivawe promena IgG vezivawa nemodifikovanih alergena
polena A. vulgaris i tri tipa alergoida malih molekulskih masa dobijenih tretmanom sa
kalijum-cijanatom, i anhidridima }ilibarne i meleinske posle izlagawa uslovima gastro-
intestinalnog trakta (saliva, `eludac, tanko crevo i kisela sredina `eluda~nog soka) i
optimizacija doma}eg ELISA testa za odre|ivawe IgG vezivawa alergena i alergoida polena
pelina. U ELISA testu je za plo~icu kuplovan ekstrakt polena pelina i kori{}eni su serumi
12 pacijenata alergi~nih na pelin. Izlagawe salivi u trajawu od 2 minuta ne uti~e na IgG
vezuju}e osobine alergena i alergoida. Izlagawe kiseloj sredini `eluda~nog soka zna~ajno
ne uti~e na IgG vezuju}e osobine alergena i alergoida polena pelina. Posle izlagawa
simuliranom `eluda~nom soku alergena i derivata u trajawu od 1 sata, procenat IgG
vezuju}ih epitopa u nemodifikovanom uzorku se smawuje na polovinu po~etne vrednosti i na
oko 30 % kod sva tri derivata. Jedino se kod karbamil-derivata % IgG vezivawa dodatno
smawuje sa produ`avawem izlagawa SGF-u. Promene u IgG vezuju}em potencijalu sva 4 uzorka
posle izlagawa simuliranim uslovima tankog creva prate sli~an obrazac.
(Primqeno 18. decembra 2003)
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